Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune booster aims to stop Cancer's return in advanced nasopharyngeal cancer

NCT ID NCT07247201

First seen Jan 04, 2026 · Last updated May 20, 2026 · Updated 20 times

Summary

This study tests whether adding Natural Killer (NK) cells from healthy donors to standard chemoradiotherapy can lower the chance of cancer returning in people with advanced nasopharyngeal cancer. About 31 participants will receive different doses of NK cells to find the safest and most effective dose. The main goal is to reduce the number of patients with detectable cancer DNA in their blood from 30% to 10% after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Singapore General Hospital

    Singapore, Singapore

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.